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Abstract
Background: Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by
deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine.
Main body: In 2017 the first European PKU Guidelines were published. These guidelines contained evidence based
and/or expert opinion recommendations regarding diagnosis, treatment and care for patients with PKU of all ages.
This manuscript is a supplement containing the practical application of the dietary treatment.
Conclusion: This handbook can support dietitians, nutritionists and physicians in starting, adjusting and
maintaining dietary treatment.
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Background
Phenylketonuria (PKU) is an autosomal, recessive, gen-
etic disorder. It is caused by a deficiency of the enzyme
phenylalanine hydroxylase which normally converts
phenylalanine to tyrosine. Deficiency of this enzyme
leads to an increased production of phenylketone bodies
(hence phenylketonuria) and accumulation of phenyl-
alanine resulting in high phenylalanine levels in the
blood and brain.
A strict, lifelong low phenylalanine diet is the principle
treatment in PKU. It may be the only treatment or used in
combination with drug treatments. This diet manual
describes the practical application of the European PKU
guidelines [1]. It provides additional references supporting
the practical recommendations as listed in the European
PKU Guidelines [1].
Principles of dietary management
The goals of dietary management are threefold:
 Prevent accumulation of excessive phenylalanine in
the blood (and therefore the brain) by strict control
of natural protein/phenylalanine intake.
 Replacement of natural protein that has been removed
from the diet with safe or phenylalanine-free protein,
called synthetic protein, amino acid mixture/supple-
ment or protein substitute. All protein substitutes are
phenylalanine-free or very low in phenylalanine.
 Attainment of normal growth and nutritional status.
This is achieved by ensuring that the diet contains a
balanced intake of all nutrients and energy. Vitamins
and minerals supplements are either added to the
protein substitute or given as a separate supplement.
Foods avoided in a low phenylalanine diet
In most people with PKU, the natural protein or dietary
phenylalanine is restricted to 25% or less of a regular
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intake to maintain blood phenylalanine concentrations
within European PKU Guidelines target ranges [1].
This usually requires avoidance/restriction of all high
protein foods such as:
 meat, chicken, fish, eggs, cheese derived from animal
milk (cow, goat, sheep).
 nuts, seeds, quinoa, wheat, oats, rye, barley.
 foods made from Quorn™ (a meat substitute made
from protein of fungal origin).
 soya, tempeh, pulses/lentils.
 gelatin and plant algae such as spirulina.
 aspartame (sweetener).
The difference between phenylalanine and
natural protein
Phenylalanine is an amino acid found in natural protein.
Different foods contain different amounts of phenylalan-
ine. In animal (e.g. meat, fish, milk and eggs) and cereal
protein sources (e.g. wheat flour and breakfast cereal),
usually the amount of food that is calculated to provide
1 g protein will supply approximately 50 mg phenylalan-
ine. Animal and cereal proteins contain around 5%
phenylalanine. This means that the phenylalanine con-
tent of these foods can be estimated from the food protein
labelling, without knowing the phenylalanine content.
However, fruits and vegetables usually contain a lower
and more variable phenylalanine content, between 20 to
40mg/per 1 g protein. Consequently the phenylalanine
content of fruit and vegetables cannot be calculated accur-
ately from the food nutritional analysis label on a packet/
container that only declares the protein content. The pro-
tein content may give the impression these foods are
higher in phenylalanine than they are (exceptions include
spinach, peas, seaweed, kale and sweetcorn which have a
higher phenylalanine/protein ratio).
Many fruits and vegetables have been analysed specif-
ically for their phenylalanine content [2–4].
Phenylalanine tolerance
Phenylalanine tolerance is the amount of phenylalanine that
can be eaten by an individual with PKU whilst maintaining
blood phenylalanine concentrations within the target treat-
ment range. Target blood phenylalanine ranges are: 120 to
360 μmol/L for children up to the age of 12 years of age
and women on a pre-conception diet or pregnancy; and
120 to 600 μmol/L for patients ≥12 years of age.
The amount of dietary phenylalanine tolerated will vary
between individuals depending on the severity of each
person’s PKU (people with mild or moderate PKU will tol-
erate more protein), the dosage, adherence and daily dis-
tribution of protein substitute, or if the drug therapy,
sapropterin or Pegvaliase for (patients ≥16 of age) is part
of the treatment regimen. It is also influenced by growth,
pregnancy, and catabolic state during illness. Most
patients on diet treatment tolerate less than 500 mg/
day phenylalanine [5]. It is expected that patients
who are responsive to sapropterin should at least
double their phenylalanine tolerance or tolerate a
safe level of protein intake as defined by the WHO/
FAO/UNU 2007 [6, 7].
Establishing maximum phenylalanine tolerance
Initial phenylalanine tolerance is established in early
infancy, with the amount of breast milk or standard
infant formula being titrated with the blood phenyl-
alanine levels. After this time, phenylalanine intake is
commonly only adjusted (increased/decreased) if
blood phenylalanine levels are consistently outside the
target range.
In practice, it is better for individuals if their phenyl-
alanine is maximized according to individual tolerance.
The more phenylalanine that is tolerated, the more ac-
ceptable the diet will be, and it will ease the practical
and social burden that the diet demands. Additionally,
more natural protein will bring nutritional benefits.
Physiologically, natural nutrients are more likely to be
more efficiently utilized.
There is evidence to suggest that some individuals
with PKU may tolerate more phenylalanine than they
have been prescribed by their health professionals [8–
10]. The only way that this can be tested is to systemat-
ically challenge individuals with additional phenylalan-
ine. It is particularly important that patients fully adhere
with their prescribed dose of protein substitute as this
will help stimulate protein synthesis.
If blood phenylalanine levels are consistently main-
tained within the lower half of target blood phenyl-
alanine levels for at least 3 months (i.e. 120 to
240 μmol/L in children up to 12 years of age and 120
to 360 μmol/L if aged ≥12), an increase of phenylalan-
ine intake by an additional 50 mg/day (approx. 1 g
natural protein) should be considered. If blood
phenylalanine levels remain within the lower half of
the target blood phenylalanine range for a further 3
consecutive blood phenylalanine levels, consideration
should be given to repeating this process.
If blood phenylalanine levels increase above target
range, then additional phenylalanine should be removed,
and the patients should return to the original prescribed
amount of phenylalanine.
These dietary changes should always be done under
the supervision of a metabolic dietitian or physician.
Phenylalanine allocation in the diet
All individuals with PKU should be allocated a daily allow-
ance of phenylalanine according to their individual toler-
ance. This enables individuals to maintain a consistent
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phenylalanine/protein intake. There are different ways of
calculating phenylalanine/protein intake and there is little
evidence to show that any method is better than another.
Phenylalanine/protein intake may be calculated by daily
grams of protein or milligrams of phenylalanine. Through-
out Europe, health professionals may use one of five sys-
tems to calculate the amount of phenylalanine eaten each
day and all systems achieve acceptable blood phenylalan-
ine control. In all systems, fruits and vegetables except
those containing phenylalanine ≥75mg/100 g can be given
without estimating their individual phenylalanine content.
This means they are not calculated as part of the daily
phenylalanine analysis. One exception is potatoes, al-
though potato varieties mainly contain ≤75mg/100 g, the
potential amount that may be eaten each day is high, so
they are calculated/measured within the daily allowance of
phenylalanine.
The 5 systems for calculating phenylalanine intake are:
 Phenylalanine exchange system (e.g. 50, 25, 20 mg of
phenylalanine).
 1 g protein exchanges.
 1 g protein exchanges (but using the phenylalanine
analyses of fruit and vegetables and calculating the
weight that provides 50 mg phenylalanine).
 Paper lists/apps listing the phenylalanine content of
foods.
 Paper lists/apps listing the protein content of foods.
Examples of how to calculate the phenylalanine in
each system are given in Appendix 1.
For regular manufactured foods e.g. sauces, breakfast
cereals, their protein food labelling is used to determine
if they are suitable for a low phenylalanine diet. This can
be challenging as sometimes protein labelling is confus-
ing. Specific considerations when using protein labelling
are given in Table 1.
Adapting phenylalanine intake if blood
phenylalanine levels are higher than
recommended
No studies have been conducted to give an indication of
how much dietary change is needed when blood phenyl-
alanine levels have been consistently above target range
for many years. The degree of change necessary may
vary from individual to individual and will also be influ-
enced by the presence of catabolism, growth and preg-
nancy. It may be that for some patients, strict adherence
with the existing dietary prescription is enough to
achieve the European PKU Guidelines target ranges.
Other patients may need a significant reduction in their
phenylalanine intake.
Several steps may be necessary to achieve blood phenyl-
alanine concentrations within target recommendations:
 Carefully document all intake of food, drink and
protein substitute. Any dietary adjustment should be
supervised by the health care team.
 The following course of action is recommended
depending on dietary history findings:
i. If a patient does not fully adhere to their usual
dietary regimen, try a 4-week trial of the ‘usual’
prescribed ‘diet’ and this should give an indicator
of what level of blood phenylalanine control can
be achieved.
ii. If a patient is eating an unrestricted diet (i.e.
meat, fish and eggs), it may be enough to
remove some or all high protein foods from the
diet and supplement with a suitable protein
substitute to bring blood phenylalanine to within
target range. Overall, the total protein intake
should supply 40% more than the FAO/WHO/
UNU [7] safe levels of protein intake accounting
for both natural protein intake and protein
equivalent from protein substitute [1].
iii. If blood phenylalanine levels remain higher than
the target ranges, the next stage is to gradually
decrease the dietary phenylalanine by 50 mg/day
(equivalent to 1 g protein) at each diet
adjustment. If after 3 consecutive blood spots,
phenylalanine levels are not within target range,
repeat this step and reduce dietary intake by a
further 50 mg/day (protein, 1 g/day), until blood
phenylalanine levels are within target range.
Dietary phenylalanine intake should not be
reduced to less than a minimum of 150 mg/day
in children under regular conditions [5]. The
minimum phenylalanine intake for adults with
PKU remains undefined.
 During any dietary change it is important to
monitor blood phenylalanine levels regularly.
Weekly blood spots are recommended.
Table 1 Considerations when interpreting protein analysis from
food labels
• It is protein rather than phenylalanine content stated on food
nutrition labels of regular foods.
• For foods produced in the EU, if the protein content is ≤0.5 g/100 g,
the food product can state it contains 0 g protein.
• The USA consider a protein content of < 1 g is insignificant and it will
not state the specific amount of protein per serving size if the protein
content is < 1 g/portion size.
• The protein content on a food label may not differentiate between
cooked or uncooked weight.
• In dry foods, protein content may be listed only after a food has been
‘theoretically’ reconstituted. Manufacturers may assume that some food
items are reconstituted with cow’s milk e.g. desserts or custards
and this is the protein value that may be stated on the label. This will
overestimate the protein content if dry foods are reconstituted with
low protein milk rather than cow’s milk.
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Low protein foods
Giving adequate energy intake from very low protein
sources is essential to meet energy requirements and to
minimise catabolism that can lead to poor blood
phenylalanine control. Maintenance of a normal en-
ergy intake is achieved by encouraging: 1) use of
‘regular’ foods which are very low in protein and 2)
special manufactured low protein foods such as bread
and pasta (Table 2).
There are many regular foods which are naturally very
low in protein that can be eaten without measurement.
These include vegan cheese made from oils and starch
(containing protein ≤0.5 g/100 g or phenylalanine ≤25
mg/100 g), butter, margarine, vegetables oils, low protein
starches (tapioca, arrowroot, corn starch, cassava flour),
sugar, jams, and honey.
Although all fruits and vegetables containing phenyl-
alanine ≤75 mg/100 g contribute a small amount of daily
phenylalanine, this is generally not enough to affect
blood phenylalanine control. These fruit and vegetable
sources are not calculated in the daily phenylalanine al-
lowance (list of suitable fruits and vegetables in Table 3),
and are given without restriction.
Potatoes are an exception (see Phenylalanine allocation
in the diet section). Also, cooked crisps (snacks) made
from vegetables such as beetroot or parsnips are concen-
trated in phenylalanine and should be calculated/mea-
sured in the daily phenylalanine allowance.
Although there is a wide range of ‘starch based’ spe-
cially manufactured low protein foods such as bread,
flour, pasta and biscuits available, patients have variable
access to these across Europe. They are generally
Table 2 Low protein foods that can be eaten without restriction in a low phenylalanine diet
Food groups Examples of low protein foods that can be eaten without calculation or restriction
in a low phenylalanine diet
Fruits and vegetables Fruits and vegetables containing phenylalanine ≤ 75mg/100 g. The exception to
this rule is potatoes, which are calculated and measured within the phenylalanine
exchange system.
Fats Butter, margarine, ghee, and vegetable oils.
Generally, any fat spread containing protein ≤ 1 g/100 g can be given in the diet
without calculating its phenylalanine/protein content [11].
Starches Cassava flour, arrowroot, sago, tapioca, and corn starch that contains protein ≤
0.5 g/100 g (phenylalanine content ≤ 25mg/100 g).
Vegan cheese Any vegan cheese that contains protein ≤ 0.5 g/100 g (or ≤ 25 mg phenylalanine
/100 g) can be given in the diet without calculating the phenylalanine/protein content.
If it contains > 0.5 g/100 g (or > 25mg phenylalanine /100 g), it should be measured/
calculated in the phenylalanine/natural protein allowance.
Sugars Sugar, glucose, jam, honey, marmalade, golden syrup, maple syrup, fruit sorbets, ice lollies,
and sweets that contains protein ≤ 0.5 g/100 g (phenylalanine content ≤ 25 mg/100 g) [11].
Vegetarian jelly /agar agar (gelatin free) If jelly/agar contains protein ≤ 0.5 g/100 g (or phenylalanine ≤ 25 mg/100 g) it can be
given in the diet without restriction. If it contains protein > 0.5 g/100 g (> 25 mg
phenylalanine /100 g, it should be measured/calculated in the phenylalanine/natural
protein allowance.
Low protein special foods A selection of low protein breads, flour mixes, pizza bases, pasta, biscuits, and egg
replacers are available. Low protein special products are allocated in the diet without
restriction if all ingredients are exchange-free e.g. food starch and oil. If they contain
protein containing ingredients and contain > 25 mg phenylalanine/100 g, their phenylalanine
should be calculated in the diet.
Herbs/spices All herbs, spices and seasonings can be incorporated into the diet without phenylalanine
calculation as the quantity used in cooking is very small.
Drinks Water, squash, lemonade, cola drinks, fruit juice, black tea, fruit tea, green tea, coffee, tonic
water, soda water and mineral water are all permitted providing they are aspartame free.
Low protein/low Phe special milk Any low protein special milk replacements that provide a total phenylalanine intake of
> 25 mg over 24 h in the volume consumed should be calculated/measured in the
phenylalanine allowance. If the total phenylalanine intake from low protein milk
replacements provides phenylalanine ≤25mg over 24 h, it can be given without
restriction [11].
Plant milk Any plant milk (e.g. coconut, rice, almond) that contains protein > 0.1 g/100ml should be
calculated/measured in the diet.
Miscellaneous Food essences and food colouring are used in small quantities and can be given
without restriction.
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expensive if not government/insurance funded or sup-
plied by the hospitals. They may provide up to 50% of
energy intake. Patients using sapropterin have less need
for special low protein foods.
Protein substitutes
The provision of an adequate dose of protein substitute,
usually based on phenylalanine-free amino acids supple-
ments, is essential to promote normal growth, prevent
protein deficiency, provide a source of tyrosine, and help
optimise blood phenylalanine control [1]. For people
with classical PKU, the protein substitute is likely to sup-
ply at least 75% of daily nitrogen requirements.
The European PKU Guidelines recommend that the
total protein intake should supply 40% more than the
FAO/WHO/UNU safe levels of protein intake [1].
However, this amount is arbitrary and unconfirmed
by research. As most of the available protein substi-
tutes are derived completely from phenylalanine-free
amino acid sources, it is recommended that a dose
higher than the FAO/WHO/UNU is given. This extra
amount compensates for the ineffective absorption of
natural/intact protein (which is mainly plant based),
poor utilisation of L-amino acids and sub-optimal en-
ergy intake [12, 13]. Body weight, age, growth and the
prescribed amount of phenylalanine/natural protein
are considered when determining the dose of protein
substitute. If an individual with PKU is obese, the
protein substitute requirement should be based on
ideal body weight (although this is an arbitrary meas-
ure, it is probably the most practical).
Timing and distribution of protein substitute intake
It is advised to give the protein substitute in small frequent
doses, 3–4 times evenly throughout the day, rather than
once or twice-daily [14]. This should be taken together
with natural protein and a carbohydrate source [15].
Types of protein substitute
Protein substitutes are in the form of amino acid pow-
ders, capsules, tablets, bars and liquids and may contain
added carbohydrate, fat, vitamins and minerals. The gen-
eral types and features of protein substitutes are outlined
in Table 4. Protein substitute adherence is an issue and
it is important that a choice of age and nutritionally ap-
propriate types and presentations are offered.
Administration of protein substitute
 Protein substitutes based on amino acids have a high
osmolality. Osmolality is the concentration of a
solution expressed as the total number of solute
particles per kilogram. Products with a high
osmolality may lead to delayed gastric emptying and
Table 3 Fruits and vegetables allowed without measurement
in PKU
Fruit
Fresh, frozen, or tinned in syrup (≤75 mg phenylalanine /100 g)
Apple Kiwi fruit Pomegranate








Cranberries Medlars Sharon fruit
Currants, dried Mulberries Star fruit
Damsons Nectarines Strawberries




Grapefruit Pears Mixed peel
Grapes Physalis Angelica




Fresh, frozen or tinned vegetables (≤75 mg phenylalanine /100 g)
Avocado Eddoes Pak choi
Artichoke Endive Parsnip
Aubergine Fennel Peppers
Baby corn Garlic Pumpkin
Beans – French, green Gherkins Radish
Beetroot Gourd Samphire
Cabbage Karela Spring onion
Carrots Kohl rabi Squash: acorn,
butternut
Capers Ladys finger (Okra) Swede
Cassava Leeks Sweet potato
Celeriac Lettuce Tomatoes
Celery Marrow Tomato puree
Chayote Mooli Turnip
Chicory Mustard and cress Watercress
Courgette Onions Water chestnuts
Cucumber Parsley and all herbs
Dudhi Parsnips
Table adapted from MacDonald A, White F. Amino acid disorders. In Shaw V,
editor. Clinical Paediatric Dietetics: Chichester: Wiley Blackwell; 2015. p. 430
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cause diarrhoea. Therefore, it is recommended that
extra water is given with each dose of protein
substitute, particularly if they are given more
concentrated than recommended by the
manufacturer.
 When water is added to a powdered protein
substitute, the tyrosine is hydrophobic and forms an
insoluble layer at the top of the solution making the
product less acceptable. Using a shaker beaker
should produce a homogenous mixture.
 Ideally, all protein substitutes should be prepared
immediately prior to use. Some preparations contain
starch that thickens with time.
 It is essential that protein substitute supplies are
carefully rotated within the home and stored
according to manufacturer’s instructions. Protein
substitute quality may be less acceptable if it is close
to its shelf life date or stored in warm conditions.
Casein glycomacropeptide (CGMP)
This is a low phenylalanine protein that is used as a pro-
tein substitute in PKU. It is a by-product of cheese whey,
and although theoretically phenylalanine-free, due to the
extraction process, some residual phenylalanine remains
in the manufactured product. CGMP protein substitutes
(± vitamins and minerals) are available in powdered, li-
quid and bar presentations.
Research has reported potential advantages of using
CGMP in PKU compared with Phe-free amino acid sup-
plements. In humans, there is evidence that CGMP has a
better taste, improves satiety and improves nitrogen reten-
tion. In animal (PKU mice) studies, there is suggestion
that CGMP reduces blood phenylalanine in the brain, im-
proves bone health and acts as prebiotic [16].
One supplier provides most of the CGMP protein; this
provides 1.8mg phenylalanine for each 1 g protein equiva-
lent [17]. Taking 60 g/day of low Phe protein from a
CGMP protein substitute (the average adolescent /adult
dose) will give an extra 108mg/day phenylalanine. The
European PKU Guidelines requires further evidence before
it can give practical recommendations on the use of CGMP
in PKU [1]. However, it is now established that CGMP,
when given for the entire dose of protein substitute, in-
creases blood phenylalanine levels in well treated children
with PKU, so care should be taken when replacing amino
acids with CGMP [18]. Nevertheless, children with milder
forms of PKU or on sapropterin therapy with a higher nat-
ural protein tolerance should tolerate the extra phenylalan-
ine provided by CGMP. No significant increase in blood
phenylalanine has been observed in adult patients using
CGMP [16], although some patients may have had sub-
optimal blood phenylalanine control prior to CGMP com-
mencement or they may have received only a partial
amount of their protein substitute intake from this source.
Aspartame content of foods/drinks
Aspartame (E951) is an artificial sweetener and 56% is
converted to free phenylalanine and so should be ex-
cluded in a low phenylalanine diet. It is added to soft
drinks, chewing gums, sweets, desserts, jelly and tabletop
sweeteners. Although aspartame should always be in-
cluded on food labels, the amount of phenylalanine it
provides remains undisclosed. The European Commis-
sion 1129/2011 issue maximum safe levels of aspartame
Table 4 Types of protein substitutes available based on phenylalanine-free amino acids
Infant protein substitutes (powder) Powdered infant formula without phenylalanine has a similar nutritional composition to regular
formula for infants without PKU.
Infant protein substitutes (liquid) Liquid infant formula without phenylalanine has a similar nutritional composition to regular
formula for infants without PKU.
Powdered weaning protein substitutes Powdered weaning (thickened) amino acids without phenylalanine. The semi-solid consistency
can be adjusted to suit the developmental age of the older baby/toddler.
Semi-solid weaning protein substitutes Ready to use semi-solid protein substitutes (amino acids mixed with fruit puree) for older babies/toddlers.
Powdered protein substitutes Powdered amino acid supplements (with or without the addition of vitamins, minerals, long chain
fatty acids, carbohydrate and fat), reconstituted with water and made into semi-solid (spoonable)
consistency or drink. They are suitable for variable age groups and are available in different flavours.
Liquid protein substitutes Ready to use liquid protein substitutes (usually with the addition of vitamins, minerals, long chain
fatty acids, carbohydrate and fat). They are suitable for variable age groups and are available in
different flavours.
Protein substitute tablets Tablets containing amino acids without phenylalanine ±vitamins and minerals. Usually
high numbers of tablets are required to meet full protein substitute requirement, but
they can be used in combination with other protein substitutes to make up requirements and aid variety.
Protein substitute bars Snack bars containing amino acids without phenylalanine. They are usually given in combination
with other protein substitutes to make up requirements and aid variety. Some may not contain added
vitamins and minerals.
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that can be added to individual categories of foods and
drinks. The types of foods that may contain phenylalan-
ine from aspartame with the maximum amount per litre
or kg of food is given in Appendix 2.
Aspartame is added to some medications. The Euro-
pean Medicines Agency summary of product character-
istics may identify the amount of phenylalanine from
aspartame added to a specific medication.
Neotame contains aspartame but the production of
phenylalanine is limited due to the inability to break
down the peptide bond between aspartic acid and
phenylalanine, reducing the production of phenylalanine.
This sweetener is safe in PKU, but is more expensive,
and therefore is used less by the industry.
Safe sweeteners for PKU are listed in Table 5.
Key points for a balanced diet/healthy living with
PKU (Fig. 1)
A balanced diet for a person with PKU should consist of
the following:
 Taking the prescribed dose of protein substitute
divided into at least 3 equal doses spread throughout
the day. The protein substitute is usually
supplemented with all vitamins, minerals and ± long
chain fatty acids to meet nutritional requirements. If
vitamins, minerals and long chain fatty acids (e.g.
docosahexaenoic acid) are not supplied by the
protein supplement, then additional
supplementation should be provided. If there is poor
adherence with the protein substitute, then
additional vitamins and minerals may be required
and biochemical nutritional status should be
carefully monitored, particularly vitamin B 12.
 Phenylalanine intake should be divided throughout
the day.
 Encourage the use of fruit and vegetables containing
phenylalanine ≤75 mg/100 g. Try and give 5
portions/day with at least one portion at each meal.
A portion of fruits and vegetables is defined as a
handful (using the patient’s hand size as a guide).
 Encourage special low protein foods such as bread
and pasta at most meals to provide calories, aid
satiety, and variety.
 Encourage additional water with protein substitute.
 Monitor blood phenylalanine levels regularly (see
European PKU guidelines for frequency), at the
same time of day but preferably fasting.
 Visit dental health practitioners annually and
maintain good oral dental hygiene practices.
Dental care
There are few studies that report the prevalence of den-
tal caries in PKU with results of studies contradictory.
There are certainly conflicting objectives in PKU care,
i.e. the need to maintain optimal blood phenylalanine
control and a low phenylalanine diet involves eating a
relatively high carbohydrate intake with a phenylalanine-
free protein substitute that is acidic and sweetened and
taken three to four times daily.
To help prevent dental problems in PKU, the following
should be encouraged:
 Rinse the mouth with water after taking protein
substitute.
 Drink water instead of juice throughout the day.
 Use a toothpaste containing fluoride.
 Encourage a good dental health routine.
 Schedule regular check-ups with a dentist from an
early age.
 After the age of 6 months, infant drinks should be
offered in a non-valve free flowing cup.
 Juices or sugary drinks should not be added to
infant bottles; protein substitutes should not be
added to infant bottles > 1 year of age. Discourage
infants from sleeping with a bottle or beaker in their
mouth.
 Sweet foods and juices are better confined to
mealtimes only. Avoid using dummies/pacifiers from
12 months of age. Using dummies after this age
encourages an open bite (which is when teeth move
to make space for the dummy).
Interpreting blood phenylalanine levels and
potential dietary adjustment
Tables 6 and 7 provide an overview of causes of high
and low blood phenylalanine levels, including appropri-
ate actions to take.
It is better to monitor trends in blood phenylalanine
levels before increasing/ decreasing natural protein/
phenylalanine intake.
Management during illness
During illness, poor appetite and low energy intake
are common and high blood phenylalanine concentra-
tions occur due to catabolism (protein breakdown).
There is little work defining the best management for
illness in PKU, but the guidelines in Table 8 may be
Table 5 Sweeteners and other sugar alternatives suitable in PKU
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helpful. All children should complete their child
health vaccination program to protect them from in-
fectious diseases which may otherwise impact on
blood phenylalanine control.
Infant feeding
Infants with untreated blood phenylalanine > 360 μmol/L
on diagnosis are treated with a low phenylalanine diet.
This involves controlling and lowering the amount of
natural protein intake by giving less breast milk or
standard infant formula in combination with a
phenylalanine-free infant formula. Infants diagnosed >
10 days of age may have a diagnostic level in excess of >
1000 μmol/L and should be given phenylalanine- free
infant formula only until blood phenylalanine levels <
1000 μmol/L are achieved. Full term infants meeting
Fig. 1 Food pyramid for PKU
Table 6 High blood phenylalanine levels and suggested actions
Cause of high blood phenylalanine levels Action
Fever/infection/trauma See section on illness management
Excess natural protein intake • Check understanding/calculation of phenylalanine allowance/ exchanges, misinterpretation/
misunderstandings of protein amounts in foods. Review portion sizes.
• Check any intentional dietary non-adherence (e.g. patient chose to eat extra protein).
• Check any special low protein products are low protein and not gluten-free by accident.
• Re-educate patient or family if necessary.
Inadequate intake of protein substitute • Check adherence (at home, nursery, school). Explore any reasons for poor adherence
and either re-educate or change type or flavour of protein substitute if appropriate.
• Check timing of protein substitute (should be spread throughout the day).
• Check patient has adequate supply of protein substitute.
• Re-calculate dose of protein substitute and increase the dosage if necessary.
Incorrect prescription of protein substitute • Occasionally the wrong protein substitute may accidentally be prescribed or given
by the pharmacist or a home delivery company.
Low energy intake/weight loss/catabolism • Increase energy intake/give extra carbohydrate. Encourage extra low protein foods
or high calorie drinks.
No obvious reason • If blood phenylalanine levels are consistently high, consider a reduction in natural
protein/phenylalanine by approx. 0.5 to 1 g/day protein or 25 to 50mg phenylalanine/day.
Table adapted from MacDonald A, White F. Amino acid disorders. In Shaw V, editor. Clinical Paediatric Dietetics: Chichester: Wiley Blackwell; 2015. p. 433
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their fluid requirements with phenylalanine- free infant
formula only, should be expected to lower blood phenyl-
alanine concentrations by around 400 μmol/L each day;
the number of days on a phenylalanine-free formula only
should be limited to avoid phenylalanine deficiency.
Breastfeeding
The European PKU guidelines recommend that breast
feeding is encouraged in preference to using standard
infant formula as a source of phenylalanine; there is con-
siderable experience of breast-feeding infants with PKU
[19–21]. Acceptable blood phenylalanine control, growth
and weight gain is attained provided it is administered
alongside a phenylalanine- free infant formula.
Breast milk has many advantages when compared to
standard infant formula:
 it is low in phenylalanine (46 mg/100 ml) and
contains long chain polyunsaturated fatty acids such
as docosahexaenoic acid.
 demand breast feeding helps establish good mother-
infant bonding.
 demand breast feeding gives the mother some
control over the feeding process.
 demand breast feeding is convenient and reduces
the number of bottle feeds required.
The most widely reported method of breast feeding
is based on the principle of giving a measured volume
Table 7 Low blood phenylalanine levels and action that should be taken
Cause of low blood phenylalanine levels Action
Inadequate intake of natural protein • Ensure all prescribed intake of natural protein/phenylalanine is eaten.
• Check understanding of exchange system/phenylalanine content of foods.
• Re-educate as necessary.
Anabolic phase, following an intercurrent infection • Ensure all prescribed intake of natural protein is eaten.
• Repeat blood phenylalanine level, and if is still low, consider an increase of natural
protein by approx. 0.5-1 g protein or 25 to 50mg/day phenylalanine but monitor
blood phenylalanine levels carefully.
Rapid growth spurt such as puberty • Increase natural protein by 0.5-1 g/day protein or phenylalanine by 25 to
50 mg/day if blood phenylalanine levels are consistently below target range.
• Increase by a further 0.5 to 1 g/day protein or phenylalanine by 25 to 50mg/day
for every 3 consecutive blood phenylalanine levels below target range.
Excess intake of infant protein substitute or overnight
consumption of infant protein substitute.
• Infants may take phenylalanine- free infant protein substitute overnight,
which may lower morning blood concentrations. Consider reducing overnight intake
if appropriate.
No obvious reason • Consider increasing natural protein by approx. 0.5-1 g protein or phenylalanine by
25 to 50 mg/day.
• Monitor blood phenylalanine levels carefully.
• It is good practice to re-check blood phenylalanine levels before any further increase
in natural protein /phenylalanine intake.
Table adapted from MacDonald A, White F. Amino acid disorders. In Shaw V, editor. Clinical Paediatric Dietetics: Chichester: Wiley Blackwell; 2015. p. 433–434
Table 8 Factors to consider during illness management in PKU
Diet Dietary advice
Protein substitute Maintenance of protein substitute intake is essential to help minimise catabolism during illness.
It is better to give this in smaller, more frequent doses throughout the day.
Protein substitute given when there is a high temperature may lead to vomiting. It is always
better to administer protein substitute when a high temperature is brought under control
post administration of anti-pyretic medication.
High carbohydrate intake Encourage frequent high carbohydrate drinks or glucose polymer solution.
Natural protein intake If on dietary treatment only, there is no need to ‘formally’ omit natural protein. In practice, a
reduced appetite leads to a lower natural protein intake.
If on sapropterin (and dietary treatment), advice is the same as for dietary treatment only.
Medications All treatment specific medication should be continued during illness.
Medications should be free of aspartame.
Continue sapropterin if prescribed.
Treat precipitating factors Antibiotics (aspartame-free if possible)a.
Anti-pyretic medication Give as necessary for high temperatures.
aBlood phenylalanine concentrations are likely to rise quickly during illness. For the immediate and short-term treatment of infections, if only aspartame
containing medicines are available, it may be better to use these until aspartame-free medication is sourced rather than leave a person with PKU without
such treatment
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of a phenylalanine- free infant formula before each
breast feed. This reduces the infant’s appetite and
hence suckling, thus lowering the amount of breast
milk taken and thereby lowering phenylalanine intake
[22]. Infants still feed on demand, varying the number
of feeds from day to day, but the phenylalanine- free
infant formula should always be given first. Blood
phenylalanine concentrations determine the volume of
phenylalanine- free infant formula required and the
feed volume commonly varies from between 30 to 60
ml. Most breast-fed infants take from 6 to 8 feeds/
daily of phenylalanine- free infant formula prior to
breast feeds. It is good practice to encourage parents
to keep records of daily feeds taken. Alternatively,
breast feeds can be given alternately with the phenyl-
alanine- free infant formula although there is less
evidence to support this. The number of breast feeds
per day is based on the blood phenylalanine results
[23].
Initially, mothers need ongoing reassurance and prac-
tical support, particularly understanding their infants’
cues for feeding and managing any common breastfeed-
ing difficulties. At first, mothers may feel their baby is
taking inadequate breast milk if they are slow to recom-
mence suckling. Blood phenylalanine concentrations
should be checked twice weekly until they have stabi-
lised. The baby requires weighing weekly for at least the
first 6 weeks. Frequent weights help provide reassurance
that the infant is gaining weight and by inference, taking
enough breast milk. Ideally, breast feeding should con-
tinue long term.
Bottle feeding
When standard infant formula is used as the phenylalan-
ine source, it is given in combination with phenylalanine
free infant formula. Fifty milligrams per kilogram of
phenylalanine from standard infant formula is adminis-
tered as a starting point, and then the dose is titrated ac-
cording to blood phenylalanine levels. The total daily
amount of infant formula is divided between 6 and 7
feeds. The rest of the fluid requirements is provided by
phenylalanine-free infant formula.
The total volume provided by the two formulas should
equate to a feed volume of 150–200 mL/kg/day. The
phenylalanine-free infant formula and the source of
phenylalanine (standard infant formula) should be given
at the same feed to deliver the correct balance of all es-
sential amino acids.
Traditionally it is recommended the standard infant for-
mula is given first to ensure the entire phenylalanine
source is completed, followed by the phenylalanine-free
infant protein substitute, which can be fed to appetite,
with guidance on an acceptable minimal volume to pro-
vide total protein requirements. Alternatively, the
calculated volume of normal infant formula and
phenylalanine-free infant protein substitute can be mixed.
This is the most popular method in Europe [22]. A disad-
vantage of mixing the source of phenylalanine (standard
infant formula) with phenylalanine-free infant formula is
that the taste may be rejected when the amount of stand-
ard infant formula is reduced or removed. Ensuring that a
minimal volume of phenylalanine-free infant formula is
consumed is just as important as ensuring that the phenyl-
alanine requirement is met but not exceeded.
The quantity of standard infant formula is adjusted by
amounts equivalent to 25-50 mg/day phenylalanine ac-
cording to blood phenylalanine concentrations. If blood
phenylalanine concentrations are < 120 μmol/L the
standard infant formula is increased. If blood phenyl-
alanine is > 360 μmol/L, the dietary phenylalanine is de-
creased by 25-50 mg/day, providing the infant is well
and drinking adequate quantities of phenylalanine-free
infant formula.
Weaning
Most PKU centres introduce solids from between 17 to
26 weeks of age which is a little earlier than the recom-
mendation of 26 weeks for the general population [9]. In
PKU, weaning development is similar to non PKU in-
fants. Evans et al. 2019 showed that progression onto
more textured foods, reduction in infant formula intake,
and self-feeding skills were comparable between infants
with PKU and non-PKU matched controls [24].
Across Europe, the most common first foods are fruit
and vegetables that contain phenylalanine ≤75mg/100 g
e.g. apple, pear, carrot, butternut squash, sweet potato.
Initially, these are offered once daily, and it is probably
better to give low protein weaning foods after the infant
phenylalanine- free infant formula and breast or stand-
ard infant formula feeds so as not to inhibit appetite for
‘milk’. Many low protein weaning foods have a low
energy density so this should be increased by adding low
protein milk, oil, butter, margarine, plant cream or low
protein cereal. Weaning foods are gradually increased to
3 times daily. Progressively, measured amounts of
phenylalanine/protein from food are introduced to re-
place the phenylalanine/protein from breast or formula
feeds. Foods such as mashed potato, peas, yoghurt, or-
dinary rusks, baby rice/baby cereal or vegetable-based
weaning foods in jars or tins are useful natural protein
exchange foods. Foods with more texture are introduced
from 6 to 8 months. Finger foods such as fingers of low
protein toast, soft fruits such as bananas, strawberries
and peaches, soft vegetable sticks, fingers of low protein
cheese, homemade low protein bread sticks, and low
protein rusks can be given from 7months of age. Water
can be given from a feeder beaker at 7 months of age.
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From 9 months, low protein pasta dishes (e.g. low
protein macaroni with low protein cheese sauce),
sandwiches made with low protein bread and low
protein cheese, chopped low protein burgers or sau-
sages with oven baked vegetable chips, or low pro-
tein mince (made with finely chopped mushrooms)
served with mashed potato and vegetables are suit-
able foods.
From the age of 6 months, it becomes necessary to
introduce a more concentrated protein substitute or
second stage protein substitute. This is common prac-
tice in Europe [9]. The amount of second stage pro-
tein substitute is gradually increased in order to meet
total protein requirements. The protein substitute can
be an unflavoured powdered protein substitute given
in the form of a semi-solid, spoonable or gel presen-
tation and most are suitable from the age of 6
months. These are mixed with a small quantity of
water and administered 3 times daily. Alternatively, a
second-stage protein substitute may be given as a
drink, although the volume required may depress the
appetite for food.
Feeding behaviour in young children
Feeding problems are common in young children with
PKU [25]. Principle problems include slowness to feed, a
poor appetite, and a limited variety of foods consumed.
Research suggests that parents’ resort to more mealtime
coercive strategies than with non PKU children to per-
suade them to eat, they give less verbal encouragement
at mealtimes and are more likely to feed their children
in isolation. Many difficulties with the administration of
the protein substitute have been described in young chil-
dren [26].
Reasons for feeding difficulties include:
 Energy content of protein substitutes. Some of the
common protein substitutes provide additional
energy from fat and carbohydrate; providing up to
25% of the energy requirements of a child aged 1 to
3-years. Parents may have unrealistic expectations of
how much food their children should eat and per-
suade them to eat when they are not hungry.
 Refusal to eat phenylalanine allowance. Parents may
be very anxious about ensuring their children eat all
their phenylalanine allowance, leading to excessive
attention and potentially resulting in repeated food
refusal. Parental force feeding may follow causing an
unpleasant mealtime situation.
 Lack of verbal encouragement at mealtimes. Parents
may prepare two meals at each family mealtime, and
for pragmatic reasons this may lead to isolated
mealtimes for children with PKU, having a negative
effect on appetite and feeding [27].
 Difficulty in giving the protein substitute. Negative
behaviours such as crying, screaming, gagging,
vomiting and deliberately spilling the protein
substitute are common in this age group.
 Food neophobia is common in children with PKU
and they reject new and novel foods in preference
for familiar ones [28, 29]. This may be associated
with lack of exposure to a wide variety of foods in
the weaning period, fear of eating unsuitable foods,
or unpleasant associations with protein substitute.
Table 9 provides an overview of strategies to im-
prove feeding problems. Table 10 provides helpful
hints for protein substitute administration with young
children.
Disordered eating in older people with PKU
Coping with and trying to adhere to a highly restrictive
dietary treatment is a huge feature of life with PKU. It is
likely to cause disordered eating by affecting feeding pat-
terns and food choices although this is an area that has
received little study in adults with PKU. Disordered eat-
ing is a descriptive phrase and not a diagnosis but is
used to label a range of irregular eating behaviours.
Symptoms of disordered eating include feelings of guilt
and shame associated with eating, preoccupation with
food, frequent dieting and anxiety associated with cer-
tain foods, and a loss of control around food. People
may have been bullied about their diet and avoid eating
in public.
Table 9 Strategies to improve feeding problems in children
with PKU
Parents should eat with children to encourage positive role modelling
and social interaction [30]. Eating together, with at least one suitable
low protein shared dish allows children to observe their parents eat and
enjoy their foods.
Develop consistent mealtime routines, so that parents help children
learn to anticipate when they will eat. The intake of sweetened drinks or
low protein milk should be controlled.
Parents should give a suitable, healthy and varied low protein diet.
Offering a child too many food choices is confusing and may cause
conflict and toddler tantrums.
Parents should allocate adequate time for each meal. When mealtimes
are too brief (< 10 min) children may not have enough time to eat,
particularly when they are acquiring self-feeding skills. In contrast, sitting
for > 20–30 min is often difficult, and mealtimes may become aversive.
Increasing familiarity with the taste of a food increases the likelihood of
acceptance. Offer new foods several times, even if initially rejected.
Children should be encouraged to ‘play with food’ e.g. decorate low
protein biscuits or garnish a low protein pizza with vegetable toppings.
This will ensure their food is fun.
Friends should be invited to low protein birthday parties, teas and
picnics. Low protein food enjoyed by others, will help food acceptance.
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This is an area that should be monitored closely in
clinics, examining food patterns and changes in nutri-
tional status. Patients with disordered eating are at
greater risk of developing clinical eating disorders and
should have an early referral to psychologists and dieti-
tians who are experts in these disorders. Mindful eating
programmes may help.
Diet during adolescence and adulthood
Following a lifelong diet is challenging. To encourage
adolescents and adults to continue their dietary treat-
ment the following should be considered:
 All the PKU team should give a consistent message
about the importance of lifelong treatment and the
need for continued dietary management.
 Patients should be encouraged to take the full dose
of prescribed protein substitute every day. They
should try alternative protein substitutes or a
combination of protein substitutes if palatability is
an issue. Explore any access problems to protein
substitute supply.
 Promote the following dietary practices:
– use of plant milks instead of animal milk like
cow’s milk. Some coffee shops offer plant milk as
an alternative to cow’s milk.
– vegetable foods/plant foods to replace and
replicate higher protein foods: e.g. jackfruit (looks
like pulled pork) in curries, stews, taco/burrito
fillings, or mushroom bolognese sauce. Advocate
the use of vegan/protein free cheese on low
protein pizza, sandwiches, toasties, macaroni
cheese. Lower protein fish substitutes (e.g.
shrimps made from konjac powder) are available.
– use of spiralised vegetables or vegetables that
have been ‘riced’, or ‘spaghetti’ squash to add
extra variety. Use lower protein vegetables/plant
foods like sweet potato and cassava to provide
bulk and aid satiety.
– the use of homemade chunky/ vegetable soups
eaten with low protein bread.
– regular, milk-based yoghurt and ice cream should
be replaced with coconut yoghurt and plant-
based ice cream.
– use of spices, seasonings and sauces to help
improve the palatability and acceptance of
vegetable dishes.
– attendance at low protein cooking classes for help
with preparing basic low protein dishes. Parents/
grandparents have a valuable role in helping with
preparation of low protein meals in all age
groups.
 Provide practical resources or suggest websites
which help with menu planning, practical food
preparation and basic shopping lists.
 Encourage online supermarket food shopping for
food. A standard shopping list can be used from
week to week; it will help ensure that suitable food
is always available.
 Organise home delivery of protein substitutes and
low protein food (if this option is available).
 Promote regular blood spot sampling.
 Suggest appropriate lower protein vegan /gluten free
options when eating out.
 At clinic visits discuss food challenges. Discuss how
events like holidays, or family gatherings have been
managed.
 Explore any financial barriers that may limit ability
to adhere to diet and signpost the patients to
appropriate advice and support.
 Ensure there is a smooth transition between
paediatric and adult care with appropriate
education, which will help equip and support the
adolescent to sustain dietary management. Useful
considerations that will assist in the transition
process are given in Table 11.
Weight management
Although overweight is not uncommon, patients
should be encouraged to contact their PKU team be-
fore commencing any weight reducing programme.
Rapid weight loss may lead to catabolism and poor
blood phenylalanine control. Weight loss should be
controlled, and blood phenylalanine levels should be
carefully managed. Weekly weight checks should be
conducted.
Encourage the following dietary changes
 Reduce sweetened drinks and replace with sugar
free/aspartame free drinks or water.
 Increase fruit and vegetables (containing
phenylalanine ≤75 mg/100 g).
Table 10 Guidance for giving protein substitute to young
children
• Establish a routine – always give protein substitute at the same time each day.
• Protein substitute should always be supervised by an adult.
• All caregivers should use the same consistent approach.
• Administer at mealtime or with a snack.
• Continue to offer even when a child refuses or is unwell. Giving a child
a ‘day-off’ from protein substitute will adversely affect their blood
phenylalanine control and deliver a wrong message i.e. that ‘it may be
okay to stop protein substitute.’ Stopping a protein substitute even for
24 h may create difficulties with its re-introduction, particularly in
young children.
• It is important that children understand from an early age that their
protein substitute is just as important as any medicine.
• It is good practice to check that no protein substitute is left behind in
containers or pouches.
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 Check the carbohydrate/energy content of the
protein substitute and consider a lower carbohydrate
preparation. Ensure that powdered preparations are
prepared with water only.
 Replace special low protein milks containing ≥60
kcal/100 ml with lower energy plant milks.
 Eat smaller portions at mealtimes but still encourage
3 meals/day using low protein pasta, rice and a low
protein bread with a lower oil content.
 Limit sugar, sweets, crisps, vegetable chips, jams,
honey, low protein chocolate or biscuits.
 Use minimal oil (preferably olive oil) or ‘light’ oil
cooking sprays.
 Encourage 30 to 45 min physical activity each day
(and at least 300 min per week).
Sport and nutrition
As there is little information about the impact of a low
phenylalanine diet affecting athletic/sporting perform-
ance, general sports nutritional requirements are modi-
fied for PKU.
The main objectives of sports nutrition and adapted
by Rocha et al., 2019 [31] for PKU are:
 Maintain a high carbohydrate diet. Carbohydrate-
rich foods should be recommended pre and post ex-
ercise and should include low fat, low-protein foods
e.g. low protein pasta. Sports drinks (aspartame-free
only) contribute to carbohydrate loading. The target
carbohydrate intake in endurance exercise of 1–2.5-
h duration is 30–60 g/h [31].
 Careful attention to hydration status. Monitor
weight pre and post exercise which will give an
indication of the fluid that should be replaced.
 Give a dose of protein substitute intake in the
immediate post-exercise recovery phase. Approxi-
mately 20–30 g of protein equivalent from protein
substitute should be ingested post exercise.
There is evidence to suggest that short acute exer-
cise does not affect blood phenylalanine levels but
the impact of endurance exercise has not been ex-
amined [32].
Pregnancy
In maternal PKU, high blood phenylalanine levels during
pregnancy have a teratogenic effect on the developing
fetus, which can result in fetal intrauterine growth re-
tardation, infant low birth weight, facial dysmorphism,
microcephaly, developmental delay, intellectual disabil-
ities, and congenital heart disease.
Table 11 Useful considerations that will assist in the transition
process between paediatric and adult care to help sustain
dietary management
Written healthcare transition plan
Patients and families need an individualized care plan and timetable for
transition. This plan should include treatment goals, a timetable for
transfer, and ensure there is a consistency of approach between all
health professionals.
The care plan should include information about target blood
phenylalanine levels, expected frequency of home blood spot taking,
educational needs and the training skills required by the patient.
Necessary knowledge and skills required for independent living
This should include information about the low phenylalanine diet e.g.
natural protein/phenylalanine allowance, dose of protein substitute,
suitable low protein foods, meal planning and food preparation,
ordering of dietary products on prescription, travel/holidays and eating
away from home.
Patients should be encouraged to use apps to record blood
phenylalanine levels, reminders for protein substitute intake and
calculate their daily protein/phenylalanine intake.
They also need a good understanding of the possible effects of high
blood phenylalanine levels on mood, cognitive and executive function.
Home blood taking/blood results
Patients should learn to take home blood samples competently, order
blood equipment and return samples according to agreed schedules.
Teenagers should discuss their own blood results directly with health
professionals. Blood results could be sent by text, telephone, or by
computer web sites (providing this is permitted by hospital IT privacy
policies) to teenagers.
Lifestyle issues
Consider overweight, body image, healthy lifestyle, exercise, extreme
sports, smoking and its cessation, alcohol, recreational drugs, pregnancy,
contraception, and genetics.
Psychological and social support
Peer support, effective strategies to cope with bullying and feelings of
social isolation should be explored.
Consider provision of ‘role model’ peer support, peer support groups,
suitable and ‘monitored’ ‘facebook’ or internet chat sites.
Information and support are required regarding changes in financial
allowances, grants, insurance or prescription charges.
Consider ‘supported’ summer camps for adolescents and adults to share
and discuss issues that concern them.
Supporting the caregivers
Involve parents/caregivers at all stages.
Give parents/caregivers information and listen to their concerns. They
will need time to develop trust in the adult IMD team.
At the start of the transition process, information should be given to
parents about the philosophy of transition, so they can prepare for the
change from the paediatric to the adult team.
Transfer timing
Consider other changes and events in a patient’s life: exams, school
leaving, university commencement, and relationships. Consider
developmental readiness.
Preparing for adult service
Teenagers should be seen in clinic without parents/caregivers but still
give parents the opportunity to discuss any concerns they may have.
The adult team should attend transition clinics and be introduced to
the family and young adult from the age of 14 years.
A pre-transfer visit to the adult clinic may be helpful with at least one
return visit made to the paediatric clinic to discuss concerns.
Ensure a member of the paediatric team attends the first few adult
clinic visits to ensure continuity of care and a familiar face.
Table adapted from MacDonald A, White F. Amino acid disorders. In Shaw V,
editor. Clinical Paediatric Dietetics: Chichester: Wiley Blackwell; 2015. p. 451
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Promoting a planned pregnancy
The European PKU guidelines (2017) state that from
the age of 12 years (beginning of puberty); all women
should receive systematic age-related sex education,
with professional counselling about the risk of unpro-
tected sexual contacts. They should be informed that
unplanned pregnancy can occur even during the first
menstrual cycle. Therefore, women need additional
professional support throughout their reproductive life
[1].
Planning a pregnancy
Women with PKU should optimize metabolic control
pre-conception and during, pregnancy. The following ac-
tions are advised:
 Meet with the PKU team 4 to 6 months prior to
their anticipated start of pregnancy so they can
provide guidance on achieving and maintaining safe
blood phenylalanine levels prior to conception.
 Aim for blood phenylalanine levels between 120 and
360 μmol/L. If blood phenylalanine levels are higher,
there should be a gradual reduction and titration of
dietary phenylalanine intake until blood
phenylalanine levels are within target range.
 Re-education of women and assessment of their
understanding about their diet is necessary even if
they already self-manage a low phenylalanine diet.
 If not established on dietary treatment, offer a
variety of protein substitutes (preferably with added
vitamins and minerals), until they find one that is
acceptable. They need to be fully aware of all the
special low protein foods available, how to access
them and any cost implications.
 Give practical advice, education and support about
menu planning, cooking and shopping, help with
specialist food orders, and weekly food shopping lists
(which could include online shopping options). This
can be through practical exercises working with
dietitians or diet assistants, short video’s, written and
pictorial information or online information and
courses.
 Teach their partner or extended family (with
consent) about the diet with information about low
protein food choices and cooking. Women with
support are more likely to cope better with a low
phenylalanine diet during pregnancy.
 Do blood spot monitoring for blood phenylalanine
at least weekly in the pre-conception period.
 Maintain blood phenylalanine in the range of 120 to
360 μmol/L prior to conception for a minimum of 2
weeks or for 3 consecutive blood phenylalanine
levels to demonstrate stability of blood
phenylalanine control. Contraception use should
continue until stability of blood phenylalanine
control is maintained.
 Assess the blood spot technique. Re-education
of blood spot taking technique may be
necessary.
 Introduce the protein substitute if women have
hyperphenylalanineamia or they have been off diet
for many years. They may have no dietary treatment
experience, or this may have been in the distant
past. It may be necessary to introduce the full dose
of protein substitute gradually over several days or
weeks.
 Start folic acid supplements.
The PKU team should:
 Provide all women with contact information for the
PKU team.
 Go through a check list of all necessary actions. A
list of necessary pre-conception activities is given in
Table 12.
Unplanned pregnancy
 If women do become pregnant unexpectedly or
suspect they are pregnant, they should know that
they must contact their PKU clinic immediately.
Women should be given an emergency card with a
guide on the action they should take with contact
details of their PKU clinic (Table 13).
 Patients should be given an emergency box
consisting of a 7-day supply of protein substitute, es-
sential low protein special foods (e. g. low protein
bread, pasta, flour and crackers), blood phenylalan-
ine monitoring equipment, low phenylalanine diet
information (including their phenylalanine allowance
and dose of protein substitute), low protein recipes
and important contact details for the PKU team and
Table 12 Check list for pre-conception diet
• Document height/weight/BMI
• Perform baseline nutritional biochemistry
• 3-day diet history to establish protein and nutritional intake /dietary
knowledge /history of diet therapy /cooking skills
• Blood phenylalanine control history
• Establish a woman’s work patterns/shift patterns and home support
• Awareness of any co-morbidities/other medications
• Dietary education
• Organise dietary supplies
• Try different protein substitutes, if appropriate
• Start strict dietary treatment
• Start folic acid
• Patient given clinic contact /helpline numbers
• Patient should be advised to continue contraception until satisfactory
blood phenylalanine is achieved.
Abbreviations: BMI Body Mass Index
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other services. Women may need further supplies of
protein substitute or special low protein foods until
their own supplies can be accessed through their
health or insurance systems.
 Baseline blood phenylalanine concentrations,
anthropometry, and nutritional biochemistry should
be established.
 Women will need to start dietary treatment
immediately. Stop all high protein foods and
commence phenylalanine restriction. As a starting
point, the initial phenylalanine allocation should be
the same as the phenylalanine tolerance when aged
< 5 years of age [33].
 Women will need to start their full requirement of
protein substitute from the day of starting dietary
treatment. It is recommended that women take ≥70
g/day total protein (calculating both natural and
amino acid intake from protein substitute). Protein
requirements have not been assessed in PKU
pregnancy and can only be extrapolated from non
PKU pregnancy. Most women will need to start on
at least 60 g/day protein equivalent from a protein
substitute, but the dose will need to be individually
calculated by the hospital team.
 Women should be given a 7-day individualized
menu plan, with a shopping list and recipe cards to
give them a guide as to what they should eat whilst
they adjust to their diet and pregnancy. Ideally a
home visiting support worker or availability of on-
line support could help women through the early
days of pregnancy.
Controlling blood phenylalanine during pregnancy
Women should be encouraged to:
 Take protein substitute as prescribed and at set
times each day, at least 3 to 4 times daily.
 Eat regular small, frequent low phenylalanine meals.
Low protein special foods are an important source
of calories and should be incorporated into the diet
each day. Weight loss can lead to higher blood
phenylalanine levels.
 Maintain frequent blood spot monitoring at least
twice weekly. Provide a calendar when to take blood
phenylalanine samples.
 Maintain phenylalanine allowance as prescribed.
Keep a record of daily phenylalanine intake.
Maintain regular communication between patient
and dietitian.
 Blood phenylalanine levels should be reported to
women immediately when analysed by the hospital
laboratory.
Adjusting phenylalanine intake during pregnancy
 It is well established that from 16 to 20 weeks’
gestation, phenylalanine tolerance is likely to
increase as foetal growth accelerates, providing
women are taking their protein substitute and
low phenylalanine foods as prescribed. Therefore,
as the baby grows it is necessary to give extra
phenylalanine to prevent phenylalanine levels
below the lower limit of the target range.
Persistent low phenylalanine levels, below
100 μmol/L, have been associated with
intrauterine growth retardation.
 Increase dietary phenylalanine prescription by at
least 50 mg/day (1 g/day protein) if blood
phenylalanine levels are around or below
120 μmol/L.
 Some women find increasing phenylalanine
allowance difficult, particularly if they have been on
a strict low phenylalanine diet all their life. They will
need guidance on when they can use higher protein
foods to make up their phenylalanine allowance. For
protein tolerance up to 10 g/day (500 mg/day
phenylalanine), it is appropriate to use foods such as
yoghurt, cow’s milk, breakfast cereals, rice, peas,
spinach, broccoli, potatoes to make up protein
allowance. When the phenylalanine allowance exceeds
500mg (>10 g natural protein)/day, introduce protein
sources such as regular bread, pasta, chick peas, cous-
cous, lentils, quinoa, Quorn; and over 1000mg/day
phenylalanine (>20 g protein), high protein foods such
as well-cooked egg, cheese, soya, and tofu may be ne-
cessary. Women should be given meal and snack ideas
listing their phenylalanine and protein content.
 At the end of pregnancy, due to hormonal causes or
a change in fetal growth, phenylalanine
concentrations may increase slightly at a stable
phenylalanine intake, usually not needing
intervention.
Table 13 Suggested emergency card for pregnancy
EMERGENCY PREGNANCY CARD




THE PKU TEAM WILL ORGANIZE TO SEE YOU WITHOUT DELAY.
Please take the following action
• If you have supplies of protein substitute, take your full daily amount
each day.
• Reduce your phenylalanine intake and speak to your PKU team. They
will give further advice.
• Take blood spots for blood phenylalanine and post to the hospital
laboratory.
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Common difficulties during pregnancy
During pregnancy, similar difficulties to non PKU preg-
nancies may occur, but their consequences may be
more important. Many women feel nauseous during
pregnancy, especially in the first trimester, causing
difficulties in protein substitute tolerance. Heartburn
and constipation may also be a problem.
Safe anti-emetic therapy and acid reducing medica-
tions should be considered with persistent vomiting
and symptoms of dyspepsia and indigestion. Advice
from the family physician or obstetrician should be
sought early. Useful strategies for persistent nausea,
vomiting, dyspepsia and indigestion are given in
Appendix 3.
Nausea and vomiting associated with pregnancy usu-
ally lessens after 12–16 weeks gestation, but symptoms
of indigestion, heartburn, and constipation are more
common after week 20 of pregnancy.
Nutritional supplements during pregnancy
Requirements of vitamins and minerals should be met
by the protein substitutes (providing the full dose is ad-
hered to) but there are some exceptions.
 All women with PKU should be given a folic acid
supplement that provides 400 μg/day from the time
of starting a pre-conception diet until 12 weeks of
pregnancy.
 There are no recommendations to give additional
tyrosine during pregnancy providing women are
taking their full requirement of protein substitute.
 Docosahexaenoic acid supplementation of 200 to
300 mg/day should be given to all pregnant women
with PKU. This is likely to be already supplied by
the protein substitute. If the protein substitute does
not contain any docosahexaenoic acid, separate
over-the counter fish oil supplements should be
given.
Weight gain in pregnancy
Overall, in maternal PKU weight gain should be similar
to the healthy population with emphasis on avoiding
weight loss particularly in the first trimester of preg-
nancy (Appendix 4).
 Energy requirements vary considerably for
individuals but low energy intake, accompanied by
weight loss is common, particularly in the first
trimester of pregnancy and this is associated with
higher blood phenylalanine concentrations.
 Inadequate energy intake may be due to dislike of
low protein foods, poor adherence with protein
substitute, limited availability of low protein foods,
inability to prepare low protein meals or poor
appetite associated with nausea and vomiting.
 If there is maternal weight loss, additional energy
from low protein foods (e.g. pasta, bread, pizza, low
protein cheese, fats, oils, low protein cream, jam,
high calorie ‘milk’ shakes or hot chocolate using low
protein milk) should be encouraged. Regular snacks
including low protein savoury or sweet muffins,
waffles, pancakes with added maple syrup /puree
fruit are also encouraged. It may be necessary to use
energy supplements such as glucose polymer/fat
emulsions. Consider using a protein substitute with
a higher energy content.
 Weight should be monitored weekly until weight
gain is satisfactory.
Obesity and maternal PKU
Any women with obesity should be encouraged to
undertake more exercise and follow a calorie restricted
diet prior to pregnancy consideration. The risks imposed
by excessive adiposity will be cumulative to those result-
ing from PKU itself.
Post pregnancy
Many women stop their dietary treatment following the
birth of their baby. They may not perceive a need for
continued treatment, or they may consider the diet too
challenging when caring for their infant. However,
health professionals should support the continuation of
dietary treatment. Women should understand that high
blood phenylalanine levels are associated with a higher
rate of depression. Maternal depression is associated
with lower rates of breast feeding, less sensitive parent-
ing style, and poor infant sleep routines. They may cope
better with the demands of parenting if blood phenyl-
alanine levels are lower.
Women should be encouraged to breast feed their in-
fants. Women with PKU (on or off dietary treatment)
can still breast feed their children and lactation is con-
sidered successful if their infant is gaining an appropri-
ate amount of weight. Even if a woman with PKU has a
PKU infant she is still able to breast feed providing
breast feeding given in combination with a
phenylalanine-free-free infant formula (see section on
infant feeding). There is anecdotal evidence (but no pub-
lished information) to support the hypothesis that breast
feeding may help to lower blood phenylalanine levels
post pregnancy. It is also likely to help maternal weight
loss (at the rate of 0.6 to 0.8 kg per month in the first 4
to 6 months of lactation). Lactation does increase energy
(by 500 kcal/day) and protein (25 g/day) requirements. A
woman’s weight, BMI, body fat percentage, and weight
gain during pregnancy do not influence breast milk pro-
duction [34].
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Table 14 Educational methods used in PKU
Teaching methods Recommendations
Verbal/face to face
Most common and effective method.
• Spend time with patients and caregivers and explain the diet
‘one to one,’ answering immediate questions. Try to make
sessions very practical using aids such as food package labelling,
web-based supermarket shops to plan meals, and demonstrate
how to make up protein substitutes.
• The end of every ‘verbal’ teaching session should include 'feed
back time’ whereby patients/caregivers’ feedback what they have learnt.
•. Patients/caregivers should be given a short, written summary (e.g. 4
to 5 action points) about advice given.
• Brief follow-up telephone calls (e.g. reiterating dietary principles) are
effective and increases adherence.
• Offer face to face teaching to grandparents, family caregivers,
nursery and school teachers.
Written materials/apps
Written materials are commonly used to
reinforce verbal education given to patients and families.
• Written information sheets should be available for caregivers,
children, adolescent and adult patients with PKU, and others
involved in management. It is also important that written materials
are available about diet and non-diet treatments.
• Dietitians should involve caregivers and patients in developing materials.
• All new written information should be pilot tested with a group of
patients/ caregivers to assess its ‘usability’ factor.
• Provide written educational packages for nurseries and schools.
• Apps that provide basic information about diet, phenylalanine
content of foods, phenylalanine counting, reminders to take protein
substitute and blood phenylalanine tracking are helpful. However, apps
are expensive to produce, and many are produced by commercial
companies so may not be independent in the information they
provide. It is important to check patient apps before recommending
to patients.
Pictures
Adding pictures to written and spoken language can
increase patient attention, comprehension, recall and
adherence.
• Pictures are useful to show step by step procedures for administering
protein substitutes, preparing recipes, and blood sample taking.
Children’s group teaching
Group practical sessions encourage self-management and help develop
social support networks.
• Practical activities should be provided. Children may plan meals, shop
for food, weigh and measure foods, and prepare meals and snacks.
• All activities should be interactive, creative, and fun.
• Attendance at a ‘PKU school/forum’ could replace a routine clinic
visit or run parallel to a clinic.
• Certificates and learning credits should be issued to encourage
attendance.
• If patients are scattered in large geographical areas, the internet and
other multi-media approaches could be used for ‘group’ teaching.
Peer support and patient advocates
These are caregivers or patients who can give practical help
and support.
• A PKU home support worker with personal experience of PKU care and
working one to one with families can help others build confidence,
improve cooking skills, diet knowledge and overall parenting skills.
• Encouraging caregivers to network with others is good for sharing
experiences, discussing coping strategies, and sharing practical
information. This is particularly important for ‘new parents’ of children
with PKU. This can be done through local and national events or
‘Facebook’, Instagram or other similar forums.
• Working with peer ‘patient ambassadors’ may act as a motivator and
guide.
• Women who have experienced pregnancy with PKU can act as role
models to teach and support girls and women with PKU.
Web-based patient education and support
Patients/caregivers can work through teaching modules at
their own pace, and gain immediate feedback from interactive
programmes
• National and international teaching PKU packages for different
ages of patients should be developed, with computer marked assessment
of knowledge learnt, with feedback to the PKU health professional team.
• For adolescents and adults with PKU, signing up to web-based
‘mindfulness’ programs to help well-being may be useful.
• European websites such as the ESPKU contain information
about travelling with PKU, information about the phenylalanine
content of common European foods, explain European food
law and implications for food labelling.
• National societies should provide more standard resources
e.g. ‘print off’ letters to give to schools, nurseries, airport security,
hotels, restaurants explaining about PKU and a low phenylalanine diet.
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Women need support during breast feeding, they
should be encouraged to take their protein substitute at
least 3 times daily as well as eating regular low protein
meals and snacks during the day.
Ideally, women should be encouraged to ‘batch cook’
and freeze low protein dishes and stock cupboards with
low protein foods whilst they are still pregnant so they are
organised for the postpartum period. They could arrange
supermarket home deliveries with regular supplies of fruit
and vegetables. Use of frozen chopped fruit and vegetables
will save on preparation time.
Women also need to be aware that the postpartum period
is a high-risk time for unintended pregnancy, so family plan-
ning and contraceptive advice remains important.
Use of sapropterin in pregnancy
Women should be tested prior to pregnancy (either by
genotyping or a BH4 loading test) [35]. If women fail to
establish metabolic control in pregnancy, in sapropterin
responsive women this drug should help lower blood
phenylalanine levels and reduce the requirement for strin-
gent diet therapy, especially, in the first 12 weeks of preg-
nancy. A higher natural protein intake is associated with
better fetal growth [36].
Support and information resources
Patient education lies at the core of managing a low
phenylalanine diet. Effective low protein education
is fundamental in bringing about a change in eating
behaviour and family lifestyle. Education should fos-
ter lifelong self-care that will ensure optimal meta-
bolic control and social outcomes (Table 14).
Useful practical resources
Scales
A good set of food digital weighing scales is import-
ant for measuring protein/phenylalanine portion sizes
or protein substitute powder accurately. It is essential
that every patient/caregiver with PKU ‘owns’ a reliable
set of food scales; it is an important investment.
Important scale characteristics are:
– has a tare feature that subtracts the weight of the
weighing container, so it provides the weight of the
ingredients only.
– numbers are clear, large and easy to read.
– it is lightweight and preferably portable.
– weighs in 1 g units.
Useful cooking equipment
A bread, soup, waffle and pancake maker, slow cooker
and food processer help save time and aid variety.
Wall organization boards
A white board that will record either 7-day menu plans,
shopping lists, date reminders for ordering of protein sub-
stitutes, specialist low protein foods or hospital appoint-
ments or recording of phenylalanine intake are invaluable.
Protein exchange calculators
This may be an app or card that has been formulated to
help patients/parents to calculate the amount of food
that will provide 1 g protein or 50 mg phenylalanine
from food labels (Fig. 2).
Alcohol
Like the rest of the population, adults with PKU are ad-
vised to take alcohol in moderation.
However, there are many suitable alcoholic drinks for
people with PKU (Table 15). Some alcoholic drinks do
contain protein such as beer and should only be taken as
part of the daily protein/phenylalanine allowance. Unfor-
tunately, there are no European food laws that mandate
that nutritional information is provided on alcoholic
drinks. This means that alcohol may not list the protein
content per 100ml on food labelling unless a manufac-
turer chooses to declare this voluntarily.
Also, some drinks contain aspartame and should be
avoided.
Conclusions
This practical resource should help health professionals de-
liver PKU dietary management according to the statements
issued by the PKU European Guidelines [1]. Dietary man-
agement, with or without sapropterin, is complex and
Table 14 Educational methods used in PKU (Continued)
Teaching methods Recommendations
• 'YouTube' educational videos are useful to explain about diet to all
ages and intellectual abilities.
Re-evaluation and audit of knowledge • It is important to re-evaluate caregiver/patient knowledge, understanding,
and interpretation of dietary principles once every 2 to 3 years. Even an
update providing new information is valuable.
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requires diligent attention to detail. Generally, across
Europe there are still many countries with limited
numbers of dietitians trained in PKU management,
and in some countries, it is the patient support
groups who provide considerable practical support
and are dependent on evidence-based resources. The
PKU Guidelines group not only considers it their re-
sponsibility to develop recommendations for manage-
ment but also to support the PKU community with
the provision of practical information to help with
guideline implementation.
Definitions
PHENYLKETONURIA, also known as PKU, is an in-
born error of metabolism due to phenylalanine hydroxy-
lase deficiency. It causes decreased metabolism of an
amino acid called phenylalanine. Untreated PKU causes
intellectual disability, seizures, and behavioural problems.
PHENYLALANINE is an essential amino acid found
in food. Major dietary sources of phenylalanine include
meat, fish, eggs, cheese, and milk. It is a precursor for
tyrosine, and subsequently the neurotransmitter dopa-
mine and the skin pigment melanin.
PROTEIN SUBSTITUTE is also referred to as med-
ical food or synthetic protein. It is a protein usually
made up of essential, semi-essential and non-essential
amino acids, without phenylalanine. Its role is to replace
natural protein.
NATURAL PROTEIN is also referred to as intact
protein. This is protein from food sources which is made
of polymer chains consisting of amino acids linked to-
gether by peptide bonds.
LOW PROTEIN SPECIAL FOODS are “dietary foods
for special medical purposes” and are defined in EC
Regulations as meaning ‘a category of foods for par-
ticular nutritional uses specifically processed or formu-
lated and intended for the dietary management of
patients and to be used under medical supervision’.
They have a low protein and phenylalanine content
and are products such as flour, bread or pasta that
are produced for the treatment in bold of PKU.
SAPROPTERIN dihydrochloride, referred to as
sapropterin, is a synthetic formulation of the active 6R-
isomer of tetrahydrobiopterin, a naturally occurring co-
factor for phenylalanine hydroxylase. Sapropterin is an
oral licensed drug for the treatment of PKU.
Supplementary information







CGMP: Casein glycomacropeptide; FAO: Food and Agriculture Organization
of the United Nations; PKU: Phenylketonuria; WHO: World Health
Organization; UNU: United Nations University
Table 15 Suitable alcoholic drinks
- Dry, sweet and vintage cidar.
- Red, white and rose wine (750 ml contains approximately 50 mg
phenylalanine).
- Champagne and prosecco.
- Port wine and sherry.
- Dry and sweet vermouth.
- Spirits: whisky, gin, vodka, rum, brandy, tequila and martini.
Please note pre-mixed drinks and cocktails (e.g. alcohol + lemonade
may contain aspartame).
Alcoholic ‘creams’ and some liqueur’s such as Amaretto and Advocaat
(containing egg) will contain protein.
Beer contains a significant amount of phenylalanine. Generally, the
stronger the beer the higher the protein content, because it
usually contains a higher malted cereal content. 600ml beer will
vary between 75 to 100mg phenylalanine.
Fig. 2 Protein exchange calculator (NSPKU website 2019, download)
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